secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001493152-26-014517
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation
--------------------------------------------------------------------------------

- Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.
- Study is the final clinical study before NDA submission to FDA under 505(b)(2) pathway for Gorlin Syndrome BCCNS.
- New global patent application planned for proprietary amorphous itraconazole formulation; owned by Inhibitor with no royalty obligations.
- Amorphous formulation aims to enhance solubility and absorption vs. crystalline itraconazole to address variable exposure.
- Study conducted with Avior Bio in Malaysia; advancing on planned timelines and budget.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/0001493152-26-014517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer